Open Nav

Please submit your session questions in advance at


  • Mark Moore, LifeEDIT

LifeEDIT is a discovery-phase pharmaceutical development company that has identified the world’s largest and most diverse set of novel CRISPR gene editing systems. We are focused on the development and commercialization of human therapeutics using our unique CRISPR technologies. In a short time LifeEDIT has already developed the world’s largest and most diverse collection of CRISPR based nucleic acid editing proteins with multiple unique PAM recognition elements. These are being deployed to develop novel therapeutics in Immuno/oncology, Neurodegenerative Diseases and select hematopoietic disorders.

  • Date:Monday, February 11
  • Time:10:45 AM - 11:00 AM
  • Room:Chelsea
  • Location:7th Floor
  • Session Type:Company Presentation
  • Please submit your session questions in advance:

    Click here.

  • Submission ID:23249
  • Company Presentation - Presentation Type:Privately Funded Company
  • Goal for Presentation:Make contacts for future R&D partnerships or fund raising.
  • Company
  • Company HQ City:Research Triangle Park
  • Company HQ State:North Carolina
  • Company HQ Country:United States
  • Total Amount Raised to Date, in All Rounds:Wholly owned subsidiary, AgBiome Inc
  • Size of Last Investment Round:$65 million to AgBiome
  • Previous and Current Investors:Fidelity, Arch, Polaris, UTIMCO, BMGF and Pontifax
  • CEO/Top Company Official:Mark Moore
  • Year Founded:2017
  • Main Therapeutic Focus:Multiple Therapeutics
  • Lead Product in Development:Hemophilia
  • Development Phase of Primary Product:Discovery
  • Number Of Unlicensed Products (For Which You Are Seeking Partners):4
Mark Moore